Business Context and Reporting Period
Company: Propanc Biopharma, Inc.
Filing Type: Form 10-Q (Unaudited)
Reporting Period: Six months ended December 31, 2024
Business Overview: A development-stage biopharmaceutical company focused on cancer treatments, specifically its lead product candidate PRP (a pro-enzyme formulation). The company has no commercial revenue and relies on financing to fund research and development (R&D).
Recent Corporate Action: A 1:60,000 reverse stock split was approved in August 2024 and became effective on January 29, 2025. All share data in this report has been retroactively adjusted.
Key Financial Metrics
| Metric | Six Months Ended Dec 31, 2024 | Six Months Ended Dec 31, 2023 |
|---|---|---|
| Revenue | $0 | $0 |
| Net Loss | $(784,493) | $(935,250) |
| Net Loss Per Share (Basic & Diluted) | $(67.64) | $(3,835.55) |
| Cash and Cash Equivalents (Ending) | $14,633 | $71,650 |
| Net Cash Used in Operating Activities | $(241,786) | $(572,342) |
| Net Cash Provided by Financing Activities | $295,515 | $624,276 |
| Total Assets | $78,533 | $72,365 |
| Total Liabilities | $4,237,292 | $3,851,424 |
| Stockholders' Deficit | $(4,158,759) | $(3,779,059) |
| Accumulated Deficit | $(67,482,713) | $(65,797,142) |
Material Changes vs. Prior Period
- Operating Expenses: Total operating expenses decreased significantly to $504,172 (from $855,283 in the prior year), driven by reductions in administration expenses ($374,352 vs. $712,013) and R&D expenses ($116,102 vs. $130,264). Management attributes this to cost-cutting measures due to limited working capital.
- Interest Expense: Decreased to $205,173 (from $442,696), primarily due to a reduction in the accretion of put premiums and amortization of debt discounts.
- Debt Position: Current liabilities increased to $4.15 million. Notably, "Loans payable - related parties" surged from $71,629 to $350,544, indicating heavy reliance on related-party financing. Several convertible notes and promissory notes are currently in default.
- Foreign Currency: The company recorded a foreign currency transaction loss of $75,698 for the six months ended Dec 31, 2024, compared to a gain of $21,198 in the prior period, due to exchange rate fluctuations between the AUD and USD.
Outlook, Risks, and Contingencies
- Going Concern: The filing explicitly states that conditions raise substantial doubt about the company's ability to continue as a going concern for at least 12 months. The company has a working capital deficit of approximately $4.14 million and cash of only $14,633.
- Liquidity Risk: The company depends entirely on debt and equity financing to fund operations. It has no revenue and is currently in default on multiple debt instruments, including the Crown Bridge Note ($65,280 principal) and various convertible notes totaling $167,200 in principal.
- Capital Raise: The company filed an S-1 registration statement in October 2024 for an underwritten offering, contingent on the reverse stock split. It has engaged EF Hutton LLC as an exclusive lead underwriter.
- Internal Controls: Management identified material weaknesses in internal controls over financial reporting, including lack of written documentation, insufficient segregation of duties, and lack of an audit committee.
- Patent Status: The company holds 84 granted/allowed patents globally for its pro-enzyme technology. A Canadian patent allowance was received in August 2024.
Investor Verification Checklist
- Cash Runway: Verify if the company has secured the financing necessary to survive the next 12 months given the $14,633 cash balance and $4.1M working capital deficit.
- Debt Default Status: Confirm the status of negotiations with lenders regarding the defaulted notes (Crown Bridge, ONE44, GS Capital) to assess the risk of acceleration or litigation.
- Reverse Stock Split Execution: Monitor the successful completion of the 1:60,000 reverse split and the subsequent listing application on the Nasdaq Capital Market.
- Related Party Transactions: Review the terms of the significant increase in related-party loans ($350k+) to ensure terms are arm's length and sustainable.
- Offering Progress: Track the status of the S-1 registration and the potential closing of the underwritten offering to determine if the company can raise the capital required for its Phase 1 clinical trials.